GSK 461364
CAS: 929095-18-1
Ref. 3D-FM43315
10mg | A consultar | ||
50mg | A consultar | ||
100mg | A consultar | ||
250mg | A consultar | ||
500mg | A consultar |
Información del producto
- 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
- 5-[6-[(4-Methylpiperazin-1-yl)methyl]-1H-benzimidazol-1-yl]-3-[[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]thiophene-2-carboxamide
- 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
- GSK 461364A
- 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-
A selective ATP-competitive inhibitor of polo-like kinase 1 (Plk1). This protein is a serine/threonine kinase that regulates cell cycle progression into mitosis and is commonly overexpressed in tumors. The Plk1 inhibition resulted in 50% growth inhibition, induction of cell cycle arrest and apoptosis in neuroblastoma cell lines at concentrations < 20 nM.
Propiedades químicas
Consulta técnica sobre: 3D-FM43315 GSK 461364
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.